Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
The company’s share price dropped after H2 results -
A new bull market for growth stocks in the US is giving issuers an opportunity to raise capital
-
Hearing aid maker raised equity to pay off debt after shareholders opposed rights issue
-
Kantonsspital Baden satisfies investor demand for long paper with pick-up
-
Bankers say a lack of investor confidence makes bigger deals more challenging
-
The Saudi drug maker's IPO is the first major flotation in the country this year
